J&J raises FY26 outlook following positive Q2

Johnson and Johnson (J&J) has achieved Q2 revenues totalling astir $25.3bn, representing a year-over-year (YoY) uptick of 6.6%, with the company's medtech division, J&J MedTech, accounting for much than a 3rd of the total.

J&J MedTech achieved revenues of astir $8.93bn successful Q2, indicative of a YoY uptick of 4.5%. Meanwhile, the remaining Q2 revenue, comprising pharma products grouped nether J&J's Innovative Medicine business, drew successful full Q2 revenues of astir $16.4bn.

With the merchandise of the beingness sciences giant's Q2 results, it present expects net to autumn successful the $11.60-$11.75 per stock scope for 2026, up from its antecedently mooted scope of $11.45-$11.65.

Despite its Q2 results prompting an uplift to its 2026 expectations, J&J's shares connected the Nasdaq were down by astir 1.5% astatine $250.09 astatine marketplace unfastened connected 15 July, versus a anterior adjacent of $253.85. J&J has a marketplace headdress of astir $611bn.

The banal deed is apt owed to the information that J&J MedTech's revenues of $8.93bn came successful beneath analysts' mean estimation of $8.97bn, according to information ‌compiled by ⁠the London Stock Exchange Group (LSEG) and seen by Reuters.

For J&J MedTech, the institution said that maturation passim the 4th was chiefly driven by segments including its electrophysiology products and Shockwave intravascular lithotripsy (IVL) strategy successful cardiovascular diseases.

J&J acquired Shockwave Medical successful a $13.1bn woody successful June 2024, inheriting its IVL catheter for treating venous pathologies including peripheral artery illness (PAD).

Shockwave Medical became the archetypal entrant successful the IVL abstraction with the European motorboat of its IVL strategy for treating PAD successful 2017, pursuing its receipt of a CE people successful 2015. In 2016, the institution became the archetypal with an IVL strategy for PAD attraction to person US Food and Drug Administration (FDA) approval, launching its archetypal IVL catheter successful the US successful 2021.

Contact lenses successful imaginativeness and trauma successful orthopaedics besides contributed. J&J MedTech's interaction lens show successful Q2 follows its precocious announced plans to outlay $1.1bn to fortify its imaginativeness manufacturing proviso successful Florida.

Usual drivers successful pharma concern

Regarding its pharma business, the institution highlighted that maturation was chiefly driven by the aforesaid halfway products arsenic successful erstwhile quarters. This comprises Darzalex (daratumumab), Carvykti (ciltacabtagene autoleucel), Tecvayli (teclistamab-cqyv ) and Rybrevant (amivantamab)/Lazcluze (lazertinib) successful oncology, Tremfya (guselkumab) and others successful immunology, and Spravato (esketamine) successful neuroscience. Calypta (lumateperone), besides successful neuroscience, has go a caller maturation operator pursuing J&J's $14.6bn acquisition of Intra-Cellular Therapies successful April 2025.